




Instance: composition-en-ee6aef82d41445c7c0958abae70ec0df
InstanceOf: CompositionUvEpi
Title: "Composition for repaglinide Package Leaflet"
Description:  "Composition for repaglinide Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "30 tablets: EU/1/09/579/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpee6aef82d41445c7c0958abae70ec0df)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - repaglinide"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Repaglinide Krka is and what it is used for</li>
<li>What you need to know before you take Repaglinide Krka</li>
<li>How to take Repaglinide Krka</li>
<li>Possible side effects</li>
<li>How to store Repaglinide Krka</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What repaglinide is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What repaglinide is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Repaglinide Krka is an oral antidiabetic medicine containing repaglinide which helps your pancreas 
produce more insulin and thereby lower your blood sugar (glucose).
Type 2 diabetes is a disease in which your pancreas does not make enough insulin to control the sugar 
in your blood or where your body does not respond normally to the insulin it produces.
Repaglinide Krka is used to control type 2 diabetes in adults as an add-on to diet and exercise: 
treatment is usually started if diet, exercise and weight reduction alone have not been able to control 
(or lower) your blood sugar.
Repaglinide Krka can also be given with metformin, another medicine for diabetes.
Repaglinide Krka has been shown to lower the blood sugar, which helps to prevent complications
from your diabetes.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take repaglinide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take repaglinide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Repaglinide Krka</p>
<p>if you are allergic to repaglinide or any of the other ingredients of this medicine (listed in 
section 6).</p>
<p>if you have type 1 diabetes.</p>
<p>if the acid level in your blood is raised (diabetic ketoacidosis).</p>
<p>if you have a severe liver disease.</p>
<p>if you take gemfibrozil (a medicine used to lower increased fat levels in the blood).
Warning and precautions
Talk to your doctor before taking Repaglinide Krka:</p>
<p>if you have liver problems. Repaglinide Krka is not recommended in patients with moderate 
liver disease. Repaglinide Krka should not be taken if you have a severe liver disease (see Do 
not take Repaglinide Krka).</p>
<p>if you have kidney problems. Repaglinide Krka should be taken with caution.</p>
<p>if you are about to have major surgery or you have recently suffered a severe illness or 
infection. At such times diabetic control may be lost.</p>
<p>if you are under 18 or over 75 years of age. Repaglinide Krka is not recommended. It has not 
been studied in these age groups.
Talk to your doctor if any of the above applies to you. Repaglinide Krka may not be suitable for you. 
Your doctor will advise you.
Children and adolescents
Do not take this medicine if you are under 18 years of age.
If you get a hypo (low blood sugar)
You may get a hypo (short for hypoglycaemia) if your blood sugar gets too low. This may happen:</p>
<p>if you take too much Repaglinide Krka</p>
<p>if you exercise more than usual</p>
<p>if you take other medicines or suffer from liver or kidney problems (see other sections of </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take repaglinide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take repaglinide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>The warning signs of a hypo may come on suddenly and can include: cold sweat, cool pale skin, 
headache, rapid heart beat, feeling sick, feeling very hungry, temporary changes in vision, drowsiness, 
unusual tiredness and weakness, nervousness or tremor, feeling anxious, feeling confused, difficulty in 
concentrating.
If your blood sugar is low or you feel a hypo coming on eat glucose tablets or a high sugar snack or 
drink, then rest.
When symptoms of hypoglycaemia have disappeared or when blood sugar levels are stabilised 
continue repaglinide treatment.
Tell people you have diabetes and that if you pass out (become unconscious) due to a hypo, they 
must turn you on your side and get medical help straight away. They must not give you any food or 
drink. It could choke you.
If severe hypoglycaemia is not treated, it can cause brain damage (temporary or permanent) and even 
death.
If you have a hypo that makes you pass out, or a lot of hypos, talk to your doctor. The amount of 
Repaglinide Krka, food or exercise may need to be adjusted.
If your blood sugar gets too high
Your blood sugar may get too high (hyperglycaemia). This may happen:</p>
<p>if you take too little Repaglinide Krka,</p>
<p>if you have an infection or a fever,</p>
<p>if you eat more than usual,</p>
<p>if you exercise less than usual.
The warning signs of too high blood sugar appear gradually. They include: increased urination, 
feeling thirsty, dry skin and dry mouth. Talk to your doctor. The amount of Repaglinide Krka, food or 
exercise may need to be adjusted.
Other medicines and Repaglinide Krka
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. 
You can take Repaglinide Krka with metformin, another medicine for diabetes, if your doctor 
prescribes it.
If you take gemfibrozil (used to lower increased fat levels in the blood) you should not take 
Repaglinide Krka.
Your body s response to Repaglinide Krka may change if you take other medicines, especially these:</p>
<p>Monoamine oxidase inhibitors (MAOI) (used to treat depression).</p>
<p>Beta blockers (used to treat high blood pressure or heart conditions).</p>
<p>ACE-inhibitors (used to treat heart conditions).</p>
<p>Salicylates (e.g. aspirin).</p>
<p>Octreotide (used to treat cancer).</p>
<p>Nonsteroidal anti-inflammatory drugs (NSAID) (a type of painkillers).</p>
<p>Steroids (anabolic steroids and corticosteroids   used for anaemia or to treat inflammation).</p>
<p>Oral contraceptives (birth control pills).</p>
<p>Thiazides (diuretics or  water pills ).</p>
<p>Danazol (used to treat breast cysts and endometriosis).</p>
<p>Thyroid products (used to treat low levels of thyroid hormones).</p>
<p>Sympathomimetics (used to treat asthma).</p>
<p>Clarithromycin, trimethoprim, rifampicin (antibiotic medicines).</p>
<p>Itraconazole, ketokonazole (antifungal medicines).</p>
<p>Gemfibrozil (used to treat high blood fats).</p>
<p>Ciclosporin (used to suppress the immune system).</p>
<p>Deferasirox (used to reduce chronic iron overload).</p>
<p>Clopidogrel (prevents blood clots).</p>
<p>Phenytoin, carbamazepine, phenobarbital (used to treat epilepsy).</p>
<p>St.John s wort (herbal medicine).
Repaglinide Krka with alcohol
Alcohol can change the ability of Repaglinide Krka to reduce the blood sugar. Watch for signs of a 
hypo.
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine.
You should not take Repaglinide Krka if you are pregnant or you are planning to become pregnant.
You should not take Repaglinide Krka if you are breast-feeding.
Driving and using machines
Your ability to drive or use a machine may be affected if your blood sugar is low or high. Bear in mind 
that you could endanger yourself or others. Please ask your doctor whether you can drive a car if you:</p>
<p>have frequent hypos,</p>
<p>have few or no warning signs of hypos.
Repaglinide Krka contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially  sodium-
free .</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure.
Your doctor will work out your dose.</p>
<p>The normal starting dose is 0.5 mg before each main meal. Swallow the tablets with a glass of 
water immediately before or up to 30 minutes before each main meal.</p>
<p>The dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to 
30 minutes before each main meal. The maximum recommended daily dose is 16 mg.
Do not take more Repaglinide Krka than your doctor has recommended.
If you take more Repaglinide Krka than you should
If you take too many tablets, your blood sugar may become too low, leading to a hypo. Please see If 
you get a hypo on what a hypo is and how to treat it.
If you forget to take Repaglinide Krka
If you miss a dose, take the next dose as usual.
Do not take a double dose to make up for a forgotten tablet.
If you stop taking Repaglinide Krka
Be aware that the desired effect is not achieved if you stop taking Repaglinide Krka. Your diabetes 
may get worse. If any change of your treatment is necessary contact your doctor first.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store repaglinide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store repaglinide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Hypoglycaemia
The most frequent side effect is hypoglycaemia which may affect up to 1 in 10 people (see If you get a 
hypo in section 2). Hypoglycaemic reactions are generally mild/moderate but may occasionally 
develop into hypoglycaemic unconsciousness or coma. If this happens, medical assistance is needed 
immediately.
Allergy
Allergy is very rare (may affect up to 1 in 10,000 people). Symptoms such as swelling, difficulty in 
breathing, rapid heartbeat, feeling dizzy and sweating could be signs of anaphylactic reaction. Contact 
a doctor immediately.
Other side effects
Common (may affect up to 1 in 10 people):</p>
<p>Stomach pain</p>
<p>Diarrhoea
Rare (may affect up to 1 in 1,000 people):</p>
<p>Acute coronary syndrome (but it may not be due to the medicine)
Very rare (may affect up to 1 in 10,000 people):</p>
<p>Vomiting</p>
<p>Constipation</p>
<p>Visual disturbances</p>
<p>Severe liver problems, abnormal liver function, such as increased liver enzymes in your blood.
Not known (frequency cannot be estimated from the available data)</p>
<p>Hypersensitivity (such as rash, itchy skin, reddening of the skin, swelling of the skin)</p>
<p>Feeling sick (nausea)
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and outer carton. The 
expiry date refers to the last day of that month.
Store in the original package in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      



Instance: composition-da-ee6aef82d41445c7c0958abae70ec0df
InstanceOf: CompositionUvEpi
Title: "Composition for repaglinide Package Leaflet"
Description:  "Composition for repaglinide Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "30 tablets: EU/1/09/579/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpee6aef82d41445c7c0958abae70ec0df)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - repaglinide"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen:
1. Virkning og anvendelse
2. Det skal du vide, før du begynder at tage Repaglinide Krka
3. Sådan skal du tage Repaglinide Krka
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What repaglinide is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What repaglinide is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Repaglinide Krka er en tablet, som indeholder repaglinid, til behandling af sukkersyge til oral
anvendelse, som får bugspytkirtlen til at producere mere insulin og derved sænker dit blodsukker 
(glukose).
Type-2 diabetes er en sygdom, hvor bugspytkirtlen ikke producerer tilstrækkelig insulin til at regulere 
dit blodsukker, eller hvor din krop ikke reagerer normalt på insulinet, den producerer.
Repaglinide Krka bruges til behandling af type 2-diabetes hos voksne som et supplement til kost og 
motion: Behandling påbegyndes normalt, hvis diæt, motion og vægttab alene ikke har været 
tilstrækkeligt til at regulere (eller reducere) blodsukkeret.
Repaglinide Krka kan også ordineres sammen med metformin, et andet lægemiddel mod sukkersyge.
Repaglinide Krka er i stand til at sænke blodsukkeret, hvilket kan hjælpe med til at forhindre 
komplikationer forårsaget af sukkersyge.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take repaglinide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take repaglinide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Repaglinide Krka

Hvis du er allergisk over for repaglinid eller et af de øvrige indholdsstoffer i dette lægemiddel 
(angivet i  punkt 6).

Hvis du har type 1-diabetes.

Hvis syreniveauet i dit blod er forhøjet (diabetisk ketoacidose).

Hvis du har en alvorlig leversygdom.

Hvis du tager gemfibrozil (et lægemiddel der anvendes til at sænke kolesterolniveauet i blodet).
28
Advarsler og forsigtighedsregler 
Kontakt lægen før du tager Repaglinide Krka. 

Hvis du har problemer med din lever. Repaglinide Krka anbefales ikke til patienter med 
moderat leversygdom. Du må ikke tage Repaglinide Krka, hvis du har en alvorlig leversygdom 
(se Tag ikke Repaglinide Krka)

Hvis du har problemer med dine nyrer. Repaglinide Krka skal tages med forsigtighed.

Hvis du står over for en stor operation eller lige har overstået en alvorlig sygdom eller 
infektion. I sådanne tilfælde kan diabetesreguleringen muligvis gå tabt.

Hvis du er under 18 år eller over 75 år gammel, anbefales det ikke at tage Repaglinide Krka, 
da der ikke er lavet studier med disse aldersgrupper.
Fortæl det til din læge, hvis noget af ovennævnte gælder for dig. Repaglinide Krka er måske ikke den 
rigtige løsning for dig. Lægen vil rådgive dig.
Børn og teenagere 
Tag ikke dette lægemiddel hvis du er under 18 år.
Hvis du får hypoglykæmi (lavt blodsukker)
Du kan få hypoglykæmi, hvis dit blodsukker bliver for lavt. Dette kan ske:

Hvis du tager for mange Repaglinide Krka

Hvis du motionerer mere end normalt

Hvis du tager anden medicin eller lider af lever- eller nyreproblemer (se andre afsnit under 
punkt. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take repaglinide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take repaglinide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Advarselstegn på hypoglykæmi kan opstå pludseligt og kan medføre: koldsved, kold bleg hud,
hovedpine, hjertebanken, kvalme, stærk fornemmelse af sult, midlertidige synsændringer, døsighed,
usædvanlig træthed og svaghed, nervøsitet eller rysten, følelse af uro, forvirring,
koncentrationsbesvær.
Hvis dit blodsukker er lavt, eller hvis du mærker symptomer på begyndende hypoglykæmi: spis 
glucosetabletter, tag en snack eller drik noget med et højt sukkerindhold. Hvil derefter.
Når symptomerne på hypoglykæmi er forsvundet og blodsukkerniveauet er stabiliseret, kan du
fortsætte behandlingen med repaglinid.
Fortæl din omgangskreds at du har sukkersyge, og at du - hvis du mister bevidstheden 
(besvimer) på grund af hypoglykæmi - skal vendes om på siden, og der straks skal tilkaldes lægehjælp. 
Du må ikke få mad eller drikke, da du kan blive kvalt.
Hvis alvorlig hypoglykæmi ikke behandles, kan det forårsage hjerneskade (midlertidig eller
permanent) og endog død.
Hvis du har hypoglykæmi som får dig til at besvime, eller hvis du har mange tilfælde af
hypoglykæmi, skal du tale med din læge. Mængden af Repaglinide Krka, mad eller motion skal
muligvis justeres.
Hvis dit blodsukker bliver for højt
Dit blodsukker kan blive for højt (hyperglykæmi). Dette kan ske:

Hvis du har taget for få Repaglinide Krka,

Hvis du har en infektion eller feber,

Hvis du spiser mere end normalt,

Hvis du motionerer mindre end normalt.
Advarselstegnene på for højt blodsukker optræder gradvist. De inkluderer: øget vandladningstrang; 
tørstfornemmelse, tør hud og tør mund. Tal med din læge da mængden af Repaglinide Krka, mad eller 
motion muligvis skal justeres.
Brug af anden medicin sammen med Repaglinide Krka
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger anden medicin, for nylig har brugt 
anden medicin eller planlægger at bruge anden medicin.
29
Du kan tage Repaglinide Krka sammen med metformin, et andet lægemiddel mod sukkersyge, hvis din 
læge ordinerer det.
Hvis du tager gemfibrozil (anvendes til at sænke kolesterolniveauet i blodet), må du ikke tage
Repaglinide Krka.
Din krops reaktion på Repaglinide Krka kan ændres, hvis du tager anden medicin, især følgende:

Monoaminooxidasehæmmere eller MAO-hæmmere (mod depression).

Betablokkere (mod forhøjet blodtryk eller hjertelidelser).

ACE-hæmmere (mod hjertelidelser).

Salicylater (f.eks. aspirin).

Oktreotid (mod kræft).

Nonsteroide antiinflammatoriske midler (NSAID) (en gruppe af smertestillende midler).

Steroider (anaboliske steroider og kortikosteroider - mod blodmangel eller mod inflammation).

Orale kontraceptiva (p-piller).

Thiazider (vanddrivende tabletter).

Danazol (mod brystcyster og endometriose).

Thyreoideapræparater (mod lavt niveau af skjoldbruskkirtlens hormoner).

Sympatomimetika (mod astma).

Clarithromycin, trimethoprim, rifampicin (antibiotiske lægemidler).

Itraconazol, ketokonazol (svampehæmmende lægemidler).

Gemfibrozil (mod kolesterol blodet).

Ciclosporin (anvendes til at undertrykke immunsystemet).

Deferasirox (anvendes til at mindske kronisk jernoverskud).

Clopidogrel (forebygger blodpropper).

Phenytoin, carbamazepin, phenobarbital (mod epilepsi).

Perikum (naturlægemiddel).
Brug af Repaglinide Krka sammen med alkohol
Alkohol kan ændre den virkning, som Repaglinide Krka har til at sænke blodsukkeret. Vær 
opmærksom på hypoglykæmiske tegn.
Graviditet og amning
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel.
Du må ikke tage Repaglinide Krka, hvis du er gravid eller planlægger at blive det.
Du må ikke tage Repaglinide Krka, hvis du ammer.
Trafik- og arbejdssikkerhed
Din evne til at køre bil, motorcykel eller cykle samt arbejde med maskiner, kan muligvis være 
påvirket, hvis dit blodsukker er for lavt eller for højt. Husk, at du kan bringe dig selv og andre i fare. 
Spørg venligst din læge om du kan køre bil, hvis du:

Ofte har hypoglykæmi

Har få eller ingen advarselstegn på hypoglykæmi.
Repaglinide Krka indeholder natrium
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen.
30
Lægen vil bestemme din dosis.

Den sædvanlige startdosis er 0,5 mg før hvert hovedmåltid. Tabletterne sluges sammen med et 
glas vand før eller op til 30 minutter før hvert hovedmåltid.

Dosis kan justeres af lægen med op til 4 mg, som skal tages umiddelbart før eller op til minutter før hvert hovedmåltid. Den højeste anbefalede daglige dosis er 16 mg.
Tag aldrig en større mængde Repaglinide Krka, end lægen har anbefalet.
Hvis du har taget for meget Repaglinide Krka
Hvis du tager for mange tabletter, kan det sænke blodsukkerniveauet for meget og medføre 
hypoglykæmi. Se venligst Hvis du får hypoglykæmi (lavt blodsukker) med hensyn til hvad 
hypoglykæmi er og hvordan det behandles.
Hvis du har glemt at tage Repaglinide Krka
Hvis du glemmer at tage en dosis, skal du tage den næste dosis som sædvanligt.
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis.
Hvis du stopper med at tage Repaglinide Krka
Vær opmærksom på, at den ønskede virkning ikke opnås, hvis du stopper med at tage Repaglinide 
Krka. Din diabetes kan muligvis forværres. Hvis det er nødvendigt at ændre din behandling, skal du
først kontakte din læge.
Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store repaglinide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store repaglinide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Hypoglykæmi
Hypoglykæmi er den mest almindelige bivirkning og kan forekomme hos mellem 1 og 10 ud af personer (se Hvis du får hypoglykæmi (lavt blodsukker) under punkt 2). Hypoglykæmiske reaktioner er 
sædvanligvis milde til moderate, men kan i nogle tilfælde udvikle sig til hypoglykæmisk bevidstløshed 
eller koma. Hvis dette sker, har du brug for øjeblikkelig lægehjælp.
Allergi
Allergi er meget sjældent (kan forekomme hos færre end 1 ud af 10.000 personer). Symptomer såsom 
hævelse, vejrtrækningsbesvær, hjertebanken, svimmelhed, svedeture, kan være tegn på en anafylaktisk 
reaktion. Kontakt straks en læge.
Andre bivirkninger
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer):

Mavesmerter

Diarré.
Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1.000 personer):

Akut koronarsyndrom (men det behøver ikke være forårsaget af lægemidlet).
Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 personer):

Opkastning

Forstoppelse

Synsforstyrrelser

Alvorlige leverproblemer, unormal leverfunktion, såsom stigning af leverenzymer i blodet.
Ikke kendt (kan ikke estimeres ud fra tilgængeligt data):
31

Hypersensitivitet (såsom udslæt, kløe, rødmen, hævelse af huden)

Kvalme.
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar dette lægemiddel utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på blisterpakningen og den ydre æske. 
Udløbsdatoen er den sidste dag i den nævnte måned.
Opbevares i den originale yderpakning for at beskytte mod lys.
Spørg apotekspersonalet hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-ee6aef82d41445c7c0958abae70ec0df
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for repaglinide Package Leaflet for language en"
Description: "ePI document Bundle for repaglinide Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-ee6aef82d41445c7c0958abae70ec0df"
* entry[0].resource = composition-en-ee6aef82d41445c7c0958abae70ec0df

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpee6aef82d41445c7c0958abae70ec0df"
* entry[=].resource = mpee6aef82d41445c7c0958abae70ec0df
                            
                    
Instance: bundlepackageleaflet-da-ee6aef82d41445c7c0958abae70ec0df
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for repaglinide Package Leaflet for language da"
Description: "ePI document Bundle for repaglinide Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-ee6aef82d41445c7c0958abae70ec0df"
* entry[0].resource = composition-da-ee6aef82d41445c7c0958abae70ec0df

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpee6aef82d41445c7c0958abae70ec0df"
* entry[=].resource = mpee6aef82d41445c7c0958abae70ec0df
                            
                    



Instance: mpee6aef82d41445c7c0958abae70ec0df
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Repaglinide Krka 0.5 mg tablets"
Description: "Repaglinide Krka 0.5 mg tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "30 tablets: EU/1/09/579/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Repaglinide Krka 0.5 mg tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: ee6aef82d41445c7c0958abae70ec0dfListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "repaglinide"

* status = #current
* mode = #working

* title = "List of all ePIs associated with repaglinide"

* subject = Reference(mpee6aef82d41445c7c0958abae70ec0df)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#repaglinide "repaglinide"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-ee6aef82d41445c7c0958abae70ec0df) // repaglinide en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-ee6aef82d41445c7c0958abae70ec0df) // repaglinide da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-ee6aef82d41445c7c0958abae70ec0df
InstanceOf: List

* insert ee6aef82d41445c7c0958abae70ec0dfListRuleset
    